[Federal Register Volume 65, Number 136 (Friday, July 14, 2000)]
[Notices]
[Page 43785]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-17918]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 19, 2000, Cambridge 
Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methaqualone (2565)........................  I
Dimethyltryptamine (7435)..................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The firm plans to manufacture small quantities of the listed 
controlled substances to produce isotope labeled standards for drug 
analysis.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than September 12, 2000.

    Dated: June 29, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 00-17918 Filed 7-13-00; 8:45 am]
BILLING CODE 4410-09-M